These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37061189)

  • 1. Psychosocial challenges affecting patient-defined medication for opioid use disorder treatment outcomes in a low-income, underserved population: Application of the social-ecological framework.
    Kleinman MB; Anvari MS; Seitz-Brown CJ; Bradley VD; Tralka H; Felton JW; Belcher AM; Greenblatt AD; Magidson JF
    J Subst Use Addict Treat; 2023 Jun; 149():209046. PubMed ID: 37061189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Sometimes you have to take the person and show them how": adapting behavioral activation for peer recovery specialist-delivery to improve methadone treatment retention.
    Kleinman MB; Anvari MS; Bradley VD; Felton JW; Belcher AM; Seitz-Brown CJ; Greenblatt AD; Dean D; Bennett M; Magidson JF
    Subst Abuse Treat Prev Policy; 2023 Mar; 18(1):15. PubMed ID: 36879304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic, social, and clinic influences on opioid treatment program retention in Dar es Salaam, Tanzania: a qualitative study.
    Knight D; Nkya IH; West NS; Yang C; Kidorf M; Latkin C; Saleem HT
    Addict Sci Clin Pract; 2023 Mar; 18(1):19. PubMed ID: 36973794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulative barriers to retention in methadone treatment among adults from rural and small urban communities.
    Pasman E; Kollin R; Broman M; Lee G; Agius E; Lister JJ; Brown S; Resko SM
    Addict Sci Clin Pract; 2022 Jul; 17(1):35. PubMed ID: 35841076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "You rise up and then you start pulling people up with you": Patient experiences with a peer-delivered behavioral activation intervention to support methadone treatment.
    Kleinman MB; Hines AC; Anvari MS; Bradley VD; Shields A; Dean D; Abidogun TM; Jack HE; Magidson JF
    Int J Drug Policy; 2023 Dec; 122():104234. PubMed ID: 37866292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Just fighting for my life to stay alive": a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories.
    Hoffman KA; Thompson E; Gaeta Gazzola M; Oberleitner LMS; Eller A; Madden LM; Marcus R; Oberleitner DE; Beitel M; Barry DT
    Addict Sci Clin Pract; 2023 Mar; 18(1):16. PubMed ID: 36944998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical stakeholders' perceptions of patient engagement in outpatient medication treatment for opioid use disorder: A qualitative study.
    Poulsen MN; Roe SA; Asdell PB; Rahm AK; Berrettini W
    J Subst Use Addict Treat; 2024 Mar; 158():209250. PubMed ID: 38072381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facilitators and barriers to collaboration between drug courts and community-based medication for opioid use disorder providers.
    Pivovarova E; Taxman FS; Boland AK; Smelson DA; Lemon SC; Friedmann PD
    J Subst Use Addict Treat; 2023 Apr; 147():208950. PubMed ID: 36804347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "In their mind, they always felt less than": The role of peers in shifting stigma as a barrier to opioid use disorder treatment retention.
    Anvari MS; Kleinman MB; Massey EC; Bradley VD; Felton JW; Belcher AM; Magidson JF
    J Subst Abuse Treat; 2022 Jul; 138():108721. PubMed ID: 35067397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of the COM-B model to patient barriers and facilitators of retention in medication treatment for opioid use disorder in rural Northeastern United States: A qualitative study.
    Poulsen MN; Asdell PB; Berrettini W; McBryan K; Rahm AK
    SSM Ment Health; 2022 Dec; 2():. PubMed ID: 36776723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medications for opioid use disorder in rural primary care practices: Patient and provider experiences.
    Bridges NC; Taber R; Foulds AL; Bear TM; Cloutier RM; McDonough BL; Gordon AJ; Cochran GT; Donohue JM; Adair D; DiDomenico E; Pringle JL; Gellad WF; Kelley D; Cole ES
    J Subst Use Addict Treat; 2023 Nov; 154():209133. PubMed ID: 37543217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians.
    Booty MD; Harp K; Batty E; Knudsen HK; Staton M; Oser CB
    J Subst Use Addict Treat; 2023 Jun; 149():209051. PubMed ID: 37084815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers.
    Calcaterra SL; Lockhart S; Callister C; Hoover K; Binswanger IA
    J Gen Intern Med; 2022 Aug; 37(11):2786-2794. PubMed ID: 34981359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient experiences of COVID-19-induced changes to methadone treatment in a large community-based opioid treatment program in Baltimore.
    Abidogun TM; Cole TO; Massey E; Kleinman M; Greenblatt AD; Seitz-Brown CJ; Magidson JF; Belcher AM
    J Subst Use Addict Treat; 2023 Feb; 145():208946. PubMed ID: 36880915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender-specific predictors of methadone treatment outcomes among African Americans at an urban clinic.
    Lister JJ; Brown S; Greenwald MK; Ledgerwood DM
    Subst Abus; 2019; 40(2):185-193. PubMed ID: 30888262
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinician identified barriers to treatment for individuals in Appalachia with opioid use disorder following release from prison: a social ecological approach.
    Bunting AM; Oser CB; Staton M; Eddens KS; Knudsen H
    Addict Sci Clin Pract; 2018 Dec; 13(1):23. PubMed ID: 30509314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experiences of three states implementing the Medicaid health home model to address opioid use disorder-Case studies in Maryland, Rhode Island, and Vermont.
    Clemans-Cope L; Wishner JB; Allen EH; Lallemand N; Epstein M; Spillman BC
    J Subst Abuse Treat; 2017 Dec; 83():27-35. PubMed ID: 29129193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mobile treatment for opioid use disorder: Implementation of community-based, same-day medication access interventions.
    Chatterjee A; Baker T; Rudorf M; Walt G; Stotz C; Martin A; Kinnard EN; McAlearney AS; Bosak J; Medley B; Pinkhover A; Taylor JL; Samet JH; Lunze K
    J Subst Use Addict Treat; 2024 Apr; 159():209272. PubMed ID: 38128649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations.
    Husain JM; Cromartie D; Fitzelle-Jones E; Brochier A; Borba CPC; Montalvo C
    J Subst Abuse Treat; 2023 Jan; 144():108918. PubMed ID: 36403456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.